Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor, is Efficacious in Mouse Models of Lupus Nephritis and Reduces Human Lymphocyte Lifespan in vitro

被引：0
|
作者：
Wang, L. [1 ]
Perper, S. [1 ]
Grebe, K. [1 ]
Schwartz, A. [1 ]
Goess, C. [1 ]
O'Connor, L. [1 ]
Hartman, D. [1 ]
Westmoreland, S. [1 ]
Graff, C. [1 ]
Souers, A. [2 ]
Leverson, J. [2 ]
Elmore, S. [2 ]
Olson, L. [1 ]
机构：
[1] Abbvie Inc, Worcester, MA USA
[2] Abbvie Inc, N Chicago, IL USA
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P4.24
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [21] Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models
    Cai, Tianyu
    Kuruvilla, Vinitha Mary
    Lin, Xiaoyu
    Uziel, Tamar
    Lu, Xin
    Zhang, Lu
    Huang, Xiaoli
    Zhang, Qi
    Cavazos, Antonio
    Han, Lina
    Shen, Yu
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [22] SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF THE BCL-2 INHIBITOR VENETOCLAX (ABT-199) IN A PHASE 1 SINGLE AND MULTIPLE ASCENDING DOSE STUDY IN FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Lu, P.
    Fleischmann, R.
    Curtis, C.
    Ignatenko, S.
    Desai, M.
    Wong, S. L.
    Grebe, K. M.
    Zeng, J.
    Medema, J.
    Stolzenbach, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 298 - 298
  • [23] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
    Lu, Peng
    Fleischmann, Roy
    Curtis, Craig
    Ignatenko, Stanislav
    Desai, Monali
    Wong, Shekman L.
    Grebe, Kristie M.
    Zeng, Jiewei
    Medema, Jeroen
    Stolzenbach, James
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [24] Targeting BET Family Bromodomain with ABBV-075 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
    Cai, Tianyu
    Kuruvilla, Vinitha Mary
    Uziel, Tamar
    Zhang, Qi
    Han, Lina
    Cavazos, Antonio
    Shen, Yu
    Konopleva, Marina
    CANCER RESEARCH, 2018, 78 (13)
  • [25] Expression of Bcl-2 pro-survival family proteins predicts pharmacological responses to ABT-199, a novel and selective Bcl-2 antagonist, in multiple myeloma models
    Sampath, Deepak
    Punnoose, Elizabeth
    Beghaert, Erwin
    Belmont, Lisa
    Peale, Franklin
    Nguyen Tan
    Chen, Jun
    Darbonne, Walter
    Yue, Peng
    Oeh, Jason
    Lee, Leslie
    Fairbrother, Wayne J.
    Souers, Andrew J.
    Elmore, Steven W.
    Leverson, Joel D.
    CANCER RESEARCH, 2013, 73 (08)
  • [26] The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA
    Muenchow, Alina
    Weller, Sandra
    Hinterleitner, Clemens
    Malenke, Elke
    Bugl, Stefanie
    Wirths, Stefan
    Mueller, Martin R.
    Schulze-Osthoff, Klaus
    Aulitzky, Walter E.
    Kopp, Hans-Georg
    Essmann, Frank
    CELL DEATH & DISEASE, 2020, 11 (08)
  • [27] The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA
    Alina Muenchow
    Sandra Weller
    Clemens Hinterleitner
    Elke Malenke
    Stefanie Bugl
    Stefan Wirths
    Martin R. Müller
    Klaus Schulze-Osthoff
    Walter E. Aulitzky
    Hans-Georg Kopp
    Frank Essmann
    Cell Death & Disease, 11
  • [28] ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+-signalling dysregulation or toxicity in pancreatic acinar cells
    Jakubowska, Monika A.
    Kerkhofs, Martijn
    Martines, Claudio
    Efremov, Dimitar G.
    Gerasimenko, Julia V.
    Gerasimenko, Oleg V.
    Petersen, Ole H.
    Bultynck, Geert
    Vervliet, Tim
    Ferdek, Pawel E.
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (22) : 4402 - 4415
  • [29] Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
    Han, Lina
    Zhang, Qi
    Shi, Ce
    Leverson, Joel
    Dail, Monique
    Phillips, Darren C.
    Chen, Jun
    Jin, Sha S.
    Jacamo, Rodrigo Omar
    Daver, Naval
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Andreeff, Michael
    Sampath, Deepak
    Konopleva, Marina
    BLOOD, 2015, 126 (23)
  • [30] Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    D C Phillips
    Y Xiao
    L T Lam
    E Litvinovich
    L Roberts-Rapp
    A J Souers
    J D Leverson
    Blood Cancer Journal, 2015, 5 : e368 - e368
12345